Skip to content Skip to navigation

Intezyne, Inc

Intezyne, Inc

Intezyne offers a new solution to oncologists, who must balance the anti-tumor activity of best-in-class chemotherapeutics with their severe toxicities. Drawing from their expertise in polymer chemistry, the Company’s founders created the IVECT™ Method to limit chemotherapeutics’ anti-tumor activity to within the tumor itself, thereby sparing healthy tissues. To date, the IVECT Method has shown positive preclinical efficacy and safety profiles in multiple cancer models versus best-in-class chemotherapeutic agents. Ultimately, the IVECT Method has demonstrated preclinical proof-of-concept in a number of therapeutic and diagnostic categories, giving the Company the opportunity to monetize this asset through licensing agreements outside of Intezyne’s primary oncology focus.

Intezyne, Inc
3720 Spectrum Blvd
Suite 104
Tampa, FL
view on map
(813) 910-2120